Harvard Bioscience (HBIO) Total Current Liabilities (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Total Current Liabilities data on file, last reported at $23.9 million in Q1 2026.

• On a quarterly basis, Total Current Liabilities fell 57.08% year-over-year to $23.9 million in Q1 2026; TTM through Mar 2026 was $23.9 million, a 57.08% decrease from a year earlier, with the FY2025 full-year figure at $22.0 million, down 60.04% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $23.9 million, up from $22.0 million in the prior quarter.
• Over the last five years, Total Current Liabilities for HBIO reached as high as $55.6 million in Q1 2025 and fell as low as $21.4 million in Q3 2022.
• Historically, Total Current Liabilities has averaged $31.1 million across 5 years, with a median of $23.9 million in 2026.
• On a YoY basis, Total Current Liabilities climbed as much as 144.03% in 2025 and fell as far as 60.04% in 2025.
• Year by year, Total Current Liabilities stood at $23.2 million in 2022, then gained by 14.16% to $26.5 million in 2023, then jumped by 107.06% to $55.0 million in 2024, then slumped by 60.04% to $22.0 million in 2025, then advanced by 8.67% to $23.9 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $23.9 million in Q1 2026, $22.0 million in Q4 2025, and $54.4 million in Q3 2025.